Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 14 · below the Ichimoku cloud · RSI 29 (oversold) · MACD above its signal · 6% above its 52-week low
None of the 29 investors followed here reported a position in VPT.V in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VPT.V trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for VPT.V.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.3 | -8.3 | 9.1 | 16.7 | -7.1 | -15.4 | 0.0 | -9.1 | -10.0 | -5.6 | −39.3% | ||
| 2025 | 0.0 | 20.0 | 41.7 | -23.5 | -23.1 | 30.0 | 7.7 | -14.3 | -16.7 | 10.0 | -18.2 | 55.6 | +40.0% |
| 2024 | -13.3 | 7.7 | -17.9 | -8.7 | 4.8 | 0.0 | -9.1 | -10.0 | -5.6 | -11.8 | -26.7 | -9.1 | −66.7% |
| 2023 | 3.7 | -7.1 | -19.2 | -23.8 | 25.0 | -30.0 | 114.3 | -16.7 | -24.0 | -10.5 | 5.9 | 66.7 | +11.1% |
| 2022 | -14.3 | -23.3 | 73.9 | -25.0 | -10.0 | -3.7 | -7.7 | 25.0 | -6.7 | 10.7 | -19.4 | 8.0 | −22.9% |
| 2021 | 111.1 | 126.3 | 2.3 | 13.6 | -20.0 | -25.0 | 3.3 | 19.4 | 32.4 | 2.0 | -28.0 | -2.8 | +288.9% |
| 2020 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.5 | 22.2 | -27.3 | 12.5 | +12.5% |
| 2019 | -6.2 | 6.7 | 0.0 | -31.2 | 27.3 | 21.4 | -5.9 | -37.5 | 10.0 | 0.0 | -9.1 | -20.0 | −50.0% |
| 2018 | -3.2 | 6.7 | -6.2 | 0.0 | -3.3 | 3.4 | -23.3 | -17.4 | 5.3 | -25.0 | 20.0 | -11.1 | −48.4% |
| 2017 | -8.3 | -9.1 | 400.0 | -26.0 | -10.8 | -9.1 | -10.0 | 0.0 | -7.4 | -28.0 | 38.9 | 24.0 | +158.3% |
| 2016 | -17.9 | 4.3 | -16.7 | 10.0 | -9.1 | -30.0 | 21.4 | -23.5 | 7.7 | 0.0 | 0.0 | -14.3 | −57.1% |
| 2015 | 0.0 | -16.7 | 20.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -16.7 | -40.0 | 0.0 | -6.7 | −53.3% |
| 2014 | 14.3 | 37.5 | -27.3 | -25.0 | 33.3 | -12.5 | -14.3 | 16.7 | 0.0 | -14.3 | 0.0 | 0.0 | −14.3% |
| 2013 | -15.4 | 0.0 | -9.1 | 0.0 | 0.0 | -30.0 | 28.6 | 11.1 | 0.0 | 40.0 | -71.4 | 75.0 | −46.2% |
| 2012 | -17.6 | 28.6 | -11.1 | -6.3 | 0.0 | 6.7 | -6.3 | 0.0 | -6.7 | -7.1 | 0.0 | 0.0 | −23.5% |
| 2011 | -15.0 | -5.9 | 6.3 | 0.0 | 0.0 | 5.9 | 22.2 | 0.0 | 4.5 | -13.0 | 5.0 | -19.0 | −15.0% |
| 2010 | 140.0 | -16.7 | 40.0 | -28.6 | 20.0 | -33.3 | 25.0 | 0.0 | 50.0 | 33.3 | -5.0 | 5.3 | +300.0% |
| 2009 | -42.9 | 200.0 | -25.0 | -11.1 | 0.0 | -25.0 | 33.3 | -25.0 | 33.3 | -12.5 | -57.1 | 66.7 | −28.6% |
| 2008 | -25.9 | 15.0 | -4.3 | 0.0 | 59.1 | -25.7 | -7.7 | -4.2 | -34.8 | -20.0 | -41.7 | 0.0 | −74.1% |
| 2007 | -12.5 | 0.0 | -22.9 | −32.5% |
No analyst coverage for this instrument.
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), which transforms standard 2D and 3D echocardiography and a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. It also provides VMS+ software, 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients. Ventripoint Diagnostics Ltd. is headquartered in Toronto, Canada.
No recent headlines.